Improving treatment safety for adults with cardiovascular disease using personalized medicine.
Official title: Development of Integrated Precision Medicine Models in Adults with Cardiovascular Disease
Funded at University of Florida · NIH-10864524 · Data updated 2026-11-12
This study is looking to help doctors better understand which heart disease patients might have bad reactions to common medications, like statins and blood thinners, by using existing health data to find patterns that can guide safer and more personalized treatments for everyone.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | July 15, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $114,375 |
| NIH project number | 1R03HL172987-01 |
| Project ID | NIH-10864524 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults with cardiovascular disease who are being treated with statins or antiplatelet medications.
✕Less likely to help
Patients who do not have cardiovascular disease or are not receiving treatment with the specified medications may not benefit from this research.
What this research studies
This research aims to enhance the identification of cardiovascular disease patients who are at risk for adverse reactions to medications like statins and antiplatelet therapies. By utilizing existing data from the All of Us Researcher Workbench, the study will analyze clinical and genetic factors that influence treatment outcomes. The goal is to develop precision medicine models that can predict which patients may experience negative side effects, thereby improving their overall treatment and care. This approach seeks to ensure that diverse populations receive equitable and effective medical care.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective medication management for patients with cardiovascular disease.
How similar studies have gone: Previous research has shown promise in using pharmacogenetic testing to improve medication outcomes, indicating that this approach could be beneficial.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Mcdonough, Caitrin W — University of Florida
- Study coordinator: Mcdonough, Caitrin W
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genetic changes in blood cells relate to heart disease in people with HIV
A study will look at how age-related blood cell mutations and large chromosomal changes might contribute to heart disease risk in people living with HIV.
-
Food allergy antibodies linked to heart disease risk in adults
Many adults have antibodies to foods without symptoms, and this study asks whether those antibodies are linked to higher risk of heart disease and related conditions.
-
Mindfulness training to lower cardiovascular risk for moms and babies during pregnancy
A mindfulness program is being tested during pregnancy to help prevent high blood pressure and heart problems for mothers and their babies.
-
Integrating clinical pharmacists into HIV care to reduce cardiovascular disease in people with HIV
A pharmacist-led program in HIV care aims to prevent and manage heart disease risks like high blood pressure, diabetes, and high cholesterol in people living with HIV.
-
Integrating heart care into HIV services in Botswana using statins
This project tests a simple, scalable approach to help people with HIV in Botswana start and stay on statin therapy to prevent heart attacks and strokes.
-
A heart-healthy program for aging HIV patients using therapy pets to help blood pressure
A study tests whether using the human-animal bond from dog ownership can help older adults living with HIV control their blood pressure and improve heart health.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.